Funding News: Three Biopharmas Score a Combined $261 Million to Advance Pipelines
Published: May 18, 2021 By Alex Keown Three companies on three separate continents raised more than $250 million to advance their scientific visions of supporting and developing new therapies for life-threatening diseases. Hummingbird Bioscience Raises $125 Million Singapore-based raised $125 million in an oversubscribed Series C financing round. The funds will be used to support the development of the company’s two lead programs and advance its early-stage clinical research. Hummingbird’s two lead assets are HMBD-001, a best-in-class HER3 antibody for NRG1-fusion and HER3-...
Source: biospace.com